Prevention of Skeletal-Related Events With Extended-Interval Denosumab: A Review of the Literature
Annals of Pharmacotherapy, 2023Objective: To review published clinical trial data related to efficacy and safety of administering denosumab at extended dosing intervals for prevention of skeletal-related events (SREs) in cancer patients. Data Sources: A literature ...
openaire +2 more sources
Management of skeletal-related events and fracture prevention in systemic mastocytosis
Osteoporosis InternationalSystemic mastocytosis is a rare condition caused by the accumulation of abnormal mast cells (MC) in various organs, including the bone. The diagnosis of mastocytosis is sometimes challenging because of the incidence rate, the heterogeneity of clinical manifestations, and the varying sensitivity of diagnostic tools.
Emily M. Lunn +3 more
openaire +2 more sources
Skeletal-related events and prognosis in urothelial cancer patients with bone metastasis
International Journal of Clinical Oncology, 2017The aim of the present study was to elucidate the details of bone metastasis (BM) and the resulting skeletal-related events (SREs), and survival and prognostic factors, in urothelial cancer (UC) patients with BM.A total of 48 UC patients with BM who were treated at our institution between 1994 and 2013 were enrolled.
Yusuke Tsuda +11 more
openaire +2 more sources
Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events
Lung Cancer, 2019SMARCA4-deficient thoracic sarcoma(DTS) is a recently identified new entity of thoracic malignancies characterized by inactivation of SMARCA4. Patients with SMARCA4-DTS have a particulary aggresive clinical course and no effective treatments. However, the detailed clinical features of SMARCA4-DTS remain unclear. Here, we report the clinical courses and
Kei Kunimasa +11 more
openaire +2 more sources
The burden of skeletal-related events in patients with prostate cancer and bone metastasis
Urologic Oncology: Seminars and Original Investigations, 2015To assess contemporary characteristics, hospital admissions, charges, and mortality in patients with prostate cancer (CaP) who have bone metastases and skeletal-related events in an observational study.Relying on the Nationwide Inpatient Sample (NIS), patients with CaP with bone metastases between 1998 and 2010 were abstracted. Patients who experienced
Florian, Roghmann +16 more
openaire +2 more sources
[Predictive factors for skeletal-related events in lung cancer].
Revue des maladies respiratoires, 2020Skeletal-related events (SRE) are common in patients with bone metastatic lung cancer and have a negative impact on quality of life and survival. The objective of this study is to identify predictive factors for SRE occurrence among this population.We conducted a 3-year retrospective study including 100 lung cancer patients with bone metastasis.Eighty ...
A, Villemain +6 more
openaire +1 more source
Predictors for Skeletal-Related Events in Patients with Advanced Multiple Myeloma.
Blood, 2007Abstract Most patients with advanced multiple myeloma (MM) develop bone lesions during their disease course. Myeloma bone disease can result in potentially debilitating and life threatening skeletal-related events (SREs) such as pathologic fracture, spinal cord compression, the need for palliative radiotherapy (RT) or surgery to bone ...
James Berenson +4 more
openaire +1 more source
Analysis of Denosumab on Skeletal-Related Events in Patients With Advanced Breast Cancer
Clinical Journal of Oncology Nursing, 2015Bisphosphonates, which are also known as osteoclast modifiers, are the standard of care in the treatment of skeletal-related events (SREs) in patients with breast cancer with metastatic bone disease. SREs are frequently a complication of advanced breast cancer, and they greatly increase morbidity and mortality in these patients.
openaire +2 more sources
PAMIDRONATE FOR THE PREVENTION OF SKELETAL- RELATED EVENTS IN MULTIPLE MYELOMA
International Journal of Technology Assessment in Health Care, 1999Multiple myeloma is a disorder of the bone marrow that is associated with bone pain and osteolytic lesions. These complications can lead to the development of pathologic fractures and severe patient morbidity. However, the results of a recent randomized trial in patients with multiple myeloma demonstrated that single 90 mg monthly doses of ...
openaire +2 more sources
Minimally Invasive Treatment of Skeletal-Related Events
2023Amata Thongphetsavong Gautam +1 more
openaire +1 more source

